Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE(2), are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE(2), promotes colon cancer.
"Cox-2/PGE2 pathways have multiple effects on tumor development , , , . Importantly, PGE2 not only promotes cell proliferation and tumor associated angiogenesis but also induces the development of MDSC , , . Over expression of Cox-2 enhances whereas a defect in Cox-2 suppresses TPA induced inflammation and DMBA/TPA induced chemical carcinogenesis , . "
[Show abstract][Hide abstract] ABSTRACT: The mechanism for inflammation associated tumor development is a central issue for tumor biology and immunology and remains to be fully elucidated. Although IL-17 is implicated in association with inflammation mediated carcinogenesis, mechanisms are largely elusive. In the current studies, we showed that IL-17 receptor-A gene deficient (IL-17R-/-) mice were resistant to chemical carcinogen-induced cutaneous carcinogenesis, a well-established inflammation associated tumor model in the skin. The deficiency in IL-17R increased the infiltration of CD8+ T cells whereas it inhibited the infiltration of CD11b+ myeloid cells and development of myeloid derived suppressor cells. Inflammation induced skin hyperplasia and production of pro-tumor inflammatory molecules were inhibited in IL-17R-/- mice. We found that pre-existing inflammation in the skin increased the susceptibility to tumor growth, which was associated with increased development of tumor specific IL-17 producing T cells. This inflammation induced susceptibility to tumor growth was abrogated in IL-17R-/- mice. Finally, neutralizing IL-17 in mice that had already developed chemical carcinogen induced skin tumors could inhibit inflammation mediated tumor progression at late stages. These results demonstrate that IL-17 mediated inflammation is an important mechanism for inflammation mediated promotion of tumor development. The study has major implications for targeting IL-17 in prevention and treatment of tumors.
PLoS ONE 02/2012; 7(2):e32126. DOI:10.1371/journal.pone.0032126 · 3.23 Impact Factor
"The potential anti-neoplastic properties of NSAIDs are attributed to their inhibition of cyclooxygenases (COX), enzymes that catalyze the synthesis of prostaglandins  , which contribute to carcinogenesis by promoting cellular proliferation, stimulating angiogenesis, and inhibiting apoptosis  . Therefore, it is biologically plausible that the putative protective effects of NSAIDs are influenced by the amount or activity of COX in cells, both partially determined by specific polymorphisms. "
[Show abstract][Hide abstract] ABSTRACT: Inflammation and non-steroidal anti-inflammatory agents (NSAIDs) may play important role in ovarian cancer. However, epidemiologic data are inconsistent, possibly reflecting inter-individual genetic differences affecting the metabolism of NSAIDs. We examined whether common polymorphisms affecting the metabolism of NSAIDs modify the association between NSAIDs and ovarian cancer risk. We genotyped 1,353 DNA samples from women who developed ovarian cancer and 1,823 samples from matched controls participating in the New England Case-Control study and the Nurses' Health Studies. Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk. Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype. Regular use of NSAIDs was not associated with ovarian cancer risk. Multivariable OR (95% CI) associated with use NSAIDs was 0.85 (95% CI: 0.71-1.02). Associations between NSAID use and ovarian cancer risk did not differ significantly across strata of genotypes. None of the studied polymorphisms was associated with ovarian cancer risk. The multivariable ORs (95% CI) associated with CYP2C9 and UGT1A6 variant genotypes were 0.99 (0.90-1.08) and 0.93 (0.82-1.05), respectively. The multivariable ORs (95% CI) associated with PPAR-γ, COX-2 -765G>C, and COX-2 Ex10+837T>C polymorphisms were 1.02 (0.87-1.20), 0.87 (0.75-1.00), and 0.97 (0.87-1.09), respectively. In this relatively large study, we found no convincing evidence supporting an association between NSAIDs use and ovarian cancer risk. Furthermore, data did not suggest interaction between selected polymorphisms and use of NSAIDs in relation to ovarian cancer risk.
International Journal of Molecular Epidemiology and Genetics 01/2010; 1(4):320-31. · 1.30 Impact Factor
"The products of the COX and LOX pathways are involved in the induction of numerous pathologies, especially inflammatory diseases. These include arthritis (Honda et al., 2006), fever, chronic pain (Mabuchi et al., 2004), sepsis, burn injury (Hahn & Gamelli, 2000), inflammatory bowel disease (Subbaramaiah et al., 2004), and carcinogenic processes in colorectal cancer (Backlund et al., 2005). In the treatment of inflammation , non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used, and are effective in the management of pain, fever, redness and edema arising as a consequence of inflammatory mediator release (Ferreira, 2002). "
[Show abstract][Hide abstract] ABSTRACT: In this study 160 plant samples representing more than 30 plant families collected from the Malaysian forests were assessed for their ability to inhibit lipoxygenase activity. The lipoxygenase inhibiting activity was measured using the 96-well microplate-based ferric oxidation of xylenol orange (FOX) assay. The screening parameters, including z' factor, indicated that the assay method adopted was robust and suitable for high-throughput screening. In the preliminary screen, four plant extracts displayed inhibitory activity of 70% or higher. The active plant extracts were isolated from Agelaea borneensis Merr. (Connaraceae) (bark) (IC50, 1.6
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.